JP2017533706A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017533706A5 JP2017533706A5 JP2017523266A JP2017523266A JP2017533706A5 JP 2017533706 A5 JP2017533706 A5 JP 2017533706A5 JP 2017523266 A JP2017523266 A JP 2017523266A JP 2017523266 A JP2017523266 A JP 2017523266A JP 2017533706 A5 JP2017533706 A5 JP 2017533706A5
- Authority
- JP
- Japan
- Prior art keywords
- cell
- tcr
- cells
- nucleic acid
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021084334A JP2021121208A (ja) | 2014-10-31 | 2021-05-19 | 改変ｔ細胞に関する方法および組成物 |
| JP2023088510A JP7757343B2 (ja) | 2014-10-31 | 2023-05-30 | 改変ｔ細胞に関する方法および組成物 |
| JP2025169833A JP2025188145A (ja) | 2014-10-31 | 2025-10-08 | 改変ｔ細胞に関する方法および組成物 |
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462073343P | 2014-10-31 | 2014-10-31 | |
| US201462073467P | 2014-10-31 | 2014-10-31 | |
| US201462073144P | 2014-10-31 | 2014-10-31 | |
| US201462073681P | 2014-10-31 | 2014-10-31 | |
| US201462073540P | 2014-10-31 | 2014-10-31 | |
| US62/073,144 | 2014-10-31 | ||
| US62/073,681 | 2014-10-31 | ||
| US62/073,343 | 2014-10-31 | ||
| US62/073,540 | 2014-10-31 | ||
| US62/073,467 | 2014-10-31 | ||
| PCT/US2015/058339 WO2016070061A1 (en) | 2014-10-31 | 2015-10-30 | Methods and compositions for modified t cells |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021084334A Division JP2021121208A (ja) | 2014-10-31 | 2021-05-19 | 改変ｔ細胞に関する方法および組成物 |
| JP2023088510A Division JP7757343B2 (ja) | 2014-10-31 | 2023-05-30 | 改変ｔ細胞に関する方法および組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017533706A JP2017533706A (ja) | 2017-11-16 |
| JP2017533706A5 true JP2017533706A5 (enExample) | 2023-06-08 |
| JP7372728B2 JP7372728B2 (ja) | 2023-11-01 |
Family
ID=55858404
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017523266A Active JP7372728B2 (ja) | 2014-10-31 | 2015-10-30 | 改変ｔ細胞に関する方法および組成物 |
| JP2021084334A Withdrawn JP2021121208A (ja) | 2014-10-31 | 2021-05-19 | 改変ｔ細胞に関する方法および組成物 |
| JP2023088510A Active JP7757343B2 (ja) | 2014-10-31 | 2023-05-30 | 改変ｔ細胞に関する方法および組成物 |
| JP2025169833A Pending JP2025188145A (ja) | 2014-10-31 | 2025-10-08 | 改変ｔ細胞に関する方法および組成物 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021084334A Withdrawn JP2021121208A (ja) | 2014-10-31 | 2021-05-19 | 改変ｔ細胞に関する方法および組成物 |
| JP2023088510A Active JP7757343B2 (ja) | 2014-10-31 | 2023-05-30 | 改変ｔ細胞に関する方法および組成物 |
| JP2025169833A Pending JP2025188145A (ja) | 2014-10-31 | 2025-10-08 | 改変ｔ細胞に関する方法および組成物 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20170258835A1 (enExample) |
| EP (2) | EP3212225B1 (enExample) |
| JP (4) | JP7372728B2 (enExample) |
| KR (1) | KR20170074243A (enExample) |
| CN (1) | CN107106670A (enExample) |
| AU (1) | AU2015338984A1 (enExample) |
| CA (1) | CA2964958A1 (enExample) |
| ES (1) | ES3061201T3 (enExample) |
| HK (1) | HK1243333A1 (enExample) |
| PL (1) | PL3212225T3 (enExample) |
| PT (1) | PT3212225T (enExample) |
| SI (1) | SI3212225T1 (enExample) |
| WO (1) | WO2016070061A1 (enExample) |
Families Citing this family (96)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112017024757A2 (pt) | 2015-05-18 | 2018-11-13 | TCR2 Therapeutics Inc. | composições e métodos para reprogramação de tcr utilizando proteínas de fusão |
| US12577289B2 (en) | 2015-06-30 | 2026-03-17 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Surrogate co-receptors for t cells and methods of use |
| US11059880B2 (en) | 2015-06-30 | 2021-07-13 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Redirected cells with MHC chimeric receptors and methods of use in immunotherapy |
| CN108348551A (zh) | 2015-08-28 | 2018-07-31 | 宾夕法尼亚大学董事会 | 表达嵌合细胞内信号传导分子的细胞的方法和组合物 |
| WO2017040324A1 (en) * | 2015-08-28 | 2017-03-09 | The Trustees Of The University Of Pennsylvania | Methods and compositions for cells expressing a chimeric intracellular signaling molecule |
| KR20180053744A (ko) | 2015-09-23 | 2018-05-23 | 사이토이뮨 테라퓨틱스 엘엘씨 | 면역 요법을 위한 flt3 유도된 car 세포 |
| US12241053B2 (en) | 2015-10-09 | 2025-03-04 | The Brigham And Women's Hospital, Inc. | Modulation of novel immune checkpoint targets |
| WO2017075465A1 (en) | 2015-10-28 | 2017-05-04 | The Broad Institute Inc. | Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3 |
| WO2017075451A1 (en) | 2015-10-28 | 2017-05-04 | The Broad Institute Inc. | Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1 |
| CA3005878A1 (en) | 2015-11-19 | 2017-05-26 | The Brigham And Women's Hospital, Inc. | Lymphocyte antigen cd5-like (cd5l)-interleukin 12b (p40) heterodimers in immunity |
| US11648268B2 (en) * | 2015-12-09 | 2023-05-16 | Memorial Sloan Kettering Cancer Center | Immune cell compositions and methods of using same |
| WO2017171631A1 (en) * | 2016-03-31 | 2017-10-05 | Lion Tcr Pte. Ltd. | Non-activated t cells expressing exogenous virus-specific t cell receptor (tcr) |
| CN109153727A (zh) * | 2016-04-15 | 2019-01-04 | 酵活有限公司 | 靶向免疫治疗剂的多特异性抗原结合构建体 |
| CN107522786A (zh) * | 2016-06-20 | 2017-12-29 | 深圳市体内生物医药科技有限公司 | 一种分子、表达其的细胞及其制备方法和用途 |
| CN107586341A (zh) * | 2016-07-08 | 2018-01-16 | 生命序有限公司 | 重组免疫检查点受体及免疫检查点抑制分子的共表达及应用 |
| CN107586342A (zh) * | 2016-07-08 | 2018-01-16 | 生命序有限公司 | 重组免疫检查点受体及其应用 |
| WO2018026953A1 (en) | 2016-08-02 | 2018-02-08 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| WO2018044866A1 (en) | 2016-08-30 | 2018-03-08 | Memorial Sloan Kettering Cancer Center | Immune cell compositions and methods of use for treating viral and other infections |
| US20190262399A1 (en) | 2016-09-07 | 2019-08-29 | The Broad Institute, Inc. | Compositions and methods for evaluating and modulating immune responses |
| MX2019003899A (es) | 2016-10-07 | 2019-08-14 | Tcr2 Therapeutics Inc | Composiciones y metodos para reprogramacion de receptores de linfocitos t mediante el uso de proteinas de fusion. |
| WO2018067991A1 (en) | 2016-10-07 | 2018-04-12 | The Brigham And Women's Hospital, Inc. | Modulation of novel immune checkpoint targets |
| WO2018089386A1 (en) | 2016-11-11 | 2018-05-17 | The Broad Institute, Inc. | Modulation of intestinal epithelial cell differentiation, maintenance and/or function through t cell action |
| AU2017363311A1 (en) | 2016-11-22 | 2019-06-13 | TCR2 Therapeutics Inc. | Compositions and methods for TCR reprogramming using fusion proteins |
| CN108264562B (zh) * | 2016-12-30 | 2021-08-10 | 惠和生物技术(上海)有限公司 | 一种结合cd3和t细胞正共刺激分子的双功能分子及其应用 |
| WO2018120842A1 (zh) * | 2016-12-30 | 2018-07-05 | 上海欣百诺生物科技有限公司 | 一种双功能分子及其应用 |
| EP3568466A4 (en) | 2017-01-10 | 2020-07-15 | The General Hospital Corporation | TARGETED T CELLS WITH CYTOTOXICITY TO IMMUNOSUPPRESSIVE CELLS |
| US11963966B2 (en) | 2017-03-31 | 2024-04-23 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating ovarian tumors |
| US11913075B2 (en) | 2017-04-01 | 2024-02-27 | The Broad Institute, Inc. | Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer |
| WO2018191558A1 (en) | 2017-04-12 | 2018-10-18 | The Broad Institute, Inc. | Modulation of epithelial cell differentiation, maintenance and/or function through t cell action, and markers and methods of use thereof |
| US20200071773A1 (en) | 2017-04-12 | 2020-03-05 | Massachusetts Eye And Ear Infirmary | Tumor signature for metastasis, compositions of matter methods of use thereof |
| CA3059444A1 (en) * | 2017-04-14 | 2018-10-18 | The General Hospital Corporation | Chimeric antigen receptor t cells targeting the tumor microenvironment |
| CA3061165A1 (en) * | 2017-04-26 | 2018-11-01 | Memorial Sloan-Kettering Cancer Center | Ready-to-use cryopreserved cells |
| WO2018209324A2 (en) | 2017-05-11 | 2018-11-15 | The Broad Institute, Inc. | Methods and compositions of use of cd8+ tumor infiltrating lymphocyte subtypes and gene signatures thereof |
| KR102379189B1 (ko) | 2017-06-13 | 2022-03-25 | 엘지디스플레이 주식회사 | 연성 표시 패널을 포함하는 롤러블 디스플레이 장치 |
| WO2018232195A1 (en) | 2017-06-14 | 2018-12-20 | The Broad Institute, Inc. | Compositions and methods targeting complement component 3 for inhibiting tumor growth |
| US12049643B2 (en) | 2017-07-14 | 2024-07-30 | The Broad Institute, Inc. | Methods and compositions for modulating cytotoxic lymphocyte activity |
| KR102521245B1 (ko) * | 2017-09-15 | 2023-04-17 | 카이트 파마 인코포레이티드 | 관리 연속성 및 신원 연속성 생물학적 샘플 추적으로 환자-특이적 면역요법 절차를 수행하기 위한 방법 및 시스템 |
| AU2018333966B2 (en) * | 2017-09-18 | 2025-04-03 | Trustees Of Boston University | Methods for treating NETosis and neutrophil activation |
| MA50188A (fr) * | 2017-09-22 | 2021-06-02 | Wuxi Biologics Ireland Ltd | Nouveaux complexes polypeptidiques bispécifiques |
| WO2019070755A1 (en) | 2017-10-02 | 2019-04-11 | The Broad Institute, Inc. | METHODS AND COMPOSITIONS FOR DETECTING AND MODULATING A GENETIC SIGNATURE OF IMMUNOTHERAPY RESISTANCE IN CANCER |
| US11732257B2 (en) | 2017-10-23 | 2023-08-22 | Massachusetts Institute Of Technology | Single cell sequencing libraries of genomic transcript regions of interest in proximity to barcodes, and genotyping of said libraries |
| WO2019094955A1 (en) | 2017-11-13 | 2019-05-16 | The Broad Institute, Inc. | Methods and compositions for targeting developmental and oncogenic programs in h3k27m gliomas |
| EP3710039A4 (en) | 2017-11-13 | 2021-08-04 | The Broad Institute, Inc. | METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER BY TARGETING THE CLEC2D-KLRB1 PATH |
| CN109970864A (zh) * | 2017-12-28 | 2019-07-05 | 上海细胞治疗研究院 | 一种双向激活共刺激分子受体及其用途 |
| US11994512B2 (en) | 2018-01-04 | 2024-05-28 | Massachusetts Institute Of Technology | Single-cell genomic methods to generate ex vivo cell systems that recapitulate in vivo biology with improved fidelity |
| CA3088832A1 (en) | 2018-01-19 | 2019-07-25 | Miltenyi Biotec B.V. & Co. KG | Regulatory t cell expressing a chimeric antigen receptor |
| KR20200130324A (ko) * | 2018-02-23 | 2020-11-18 | 에이치 리 모피트 캔서 센터 앤드 리서어치 인스티튜트 아이엔씨 | Cd83-결합 키메라 항원 수용체 |
| CA3092794A1 (en) | 2018-03-01 | 2019-09-06 | University Of Kansas | Techniques for generating cell-based therapeutics using recombinant t cell receptor genes |
| EP3765093A4 (en) * | 2018-03-15 | 2021-12-08 | Fundamental Solutions Corporation | PROGRAMMABLE IMMUNOCYTE RECEPTOR COMPLEX SYSTEM |
| US11957695B2 (en) | 2018-04-26 | 2024-04-16 | The Broad Institute, Inc. | Methods and compositions targeting glucocorticoid signaling for modulating immune responses |
| WO2019222642A1 (en) * | 2018-05-18 | 2019-11-21 | Senti Biosciences, Inc. | Engineered immune cells and methods of use |
| US20210371932A1 (en) | 2018-06-01 | 2021-12-02 | Massachusetts Institute Of Technology | Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients |
| US12036240B2 (en) | 2018-06-14 | 2024-07-16 | The Broad Institute, Inc. | Compositions and methods targeting complement component 3 for inhibiting tumor growth |
| WO2020033273A1 (en) * | 2018-08-04 | 2020-02-13 | AbCyte Therapeutics Inc. | Multi-function and multi-targeting car system and methods for use thereof |
| US20220347213A1 (en) * | 2018-08-08 | 2022-11-03 | Nantbio, Inc. | Recombinant CD1-Restricted T Cells And Methods |
| WO2020072700A1 (en) | 2018-10-02 | 2020-04-09 | Dana-Farber Cancer Institute, Inc. | Hla single allele lines |
| WO2020081730A2 (en) | 2018-10-16 | 2020-04-23 | Massachusetts Institute Of Technology | Methods and compositions for modulating microenvironment |
| US20220062394A1 (en) | 2018-12-17 | 2022-03-03 | The Broad Institute, Inc. | Methods for identifying neoantigens |
| CN111378622B (zh) * | 2018-12-29 | 2022-12-02 | 华东师范大学 | 核酸编码的car-t细胞及其制备方法和应用 |
| CN109722437B (zh) * | 2018-12-29 | 2020-01-07 | 广州百暨基因科技有限公司 | 一种通用型car-t细胞及其制备方法和用途 |
| US11739156B2 (en) | 2019-01-06 | 2023-08-29 | The Broad Institute, Inc. Massachusetts Institute of Technology | Methods and compositions for overcoming immunosuppression |
| WO2020156405A1 (en) * | 2019-01-28 | 2020-08-06 | Wuxi Biologics (Shanghai) Co. Ltd. | Novel bispecific cd3/cd20 polypeptide complexes |
| WO2020186101A1 (en) | 2019-03-12 | 2020-09-17 | The Broad Institute, Inc. | Detection means, compositions and methods for modulating synovial sarcoma cells |
| EP3942023A1 (en) | 2019-03-18 | 2022-01-26 | The Broad Institute, Inc. | Compositions and methods for modulating metabolic regulators of t cell pathogenicity |
| EP3952887A4 (en) | 2019-04-12 | 2023-05-03 | Emory University | COMPOSITIONS AND METHODS FOR PROMOTING THE CYTOTOXICITY OF HEMATOPOIETIC CELLS |
| US20220235340A1 (en) | 2019-05-20 | 2022-07-28 | The Broad Institute, Inc. | Novel crispr-cas systems and uses thereof |
| WO2020243371A1 (en) | 2019-05-28 | 2020-12-03 | Massachusetts Institute Of Technology | Methods and compositions for modulating immune responses |
| WO2021030627A1 (en) | 2019-08-13 | 2021-02-18 | The General Hospital Corporation | Methods for predicting outcomes of checkpoint inhibition and treatment thereof |
| US12421557B2 (en) | 2019-08-16 | 2025-09-23 | The Broad Institute, Inc. | Methods for predicting outcomes and treating colorectal cancer using a cell atlas |
| US12018081B1 (en) * | 2019-08-28 | 2024-06-25 | The Regents Of The University Of Colorado, A Body Corporate | Photoconjugation reactions for modification of specific proteins on live cells |
| WO2021041922A1 (en) | 2019-08-30 | 2021-03-04 | The Broad Institute, Inc. | Crispr-associated mu transposase systems |
| AU2020347171A1 (en) | 2019-09-11 | 2022-03-10 | The Trustees Of The University Of Pennsylvania | Compositions and methods comprising prostate stem cell antigen (PSCA) chimeric antigen receptors (CARs) |
| CN112500492B (zh) * | 2019-09-13 | 2023-08-04 | 中国科学院分子细胞科学卓越创新中心 | 一种嵌合抗原受体及其用途 |
| US12297426B2 (en) | 2019-10-01 | 2025-05-13 | The Broad Institute, Inc. | DNA damage response signature guided rational design of CRISPR-based systems and therapies |
| US12394502B2 (en) | 2019-10-02 | 2025-08-19 | The General Hospital Corporation | Method for predicting HLA-binding peptides using protein structural features |
| US12195725B2 (en) | 2019-10-03 | 2025-01-14 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for modulating and detecting tissue specific TH17 cell pathogenicity |
| US11981922B2 (en) | 2019-10-03 | 2024-05-14 | Dana-Farber Cancer Institute, Inc. | Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment |
| US11793787B2 (en) | 2019-10-07 | 2023-10-24 | The Broad Institute, Inc. | Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis |
| US11844800B2 (en) | 2019-10-30 | 2023-12-19 | Massachusetts Institute Of Technology | Methods and compositions for predicting and preventing relapse of acute lymphoblastic leukemia |
| US12165747B2 (en) | 2020-01-23 | 2024-12-10 | The Broad Institute, Inc. | Molecular spatial mapping of metastatic tumor microenvironment |
| JP2023522330A (ja) | 2020-04-17 | 2023-05-30 | シティ・オブ・ホープ | Ｆｌｔ３陽性悪性腫瘍を処置するためのｆｌｔ３標的化キメラ抗原受容体改変細胞 |
| CN111574616B (zh) * | 2020-06-17 | 2021-02-02 | 深圳豪石生物科技有限公司 | 分离的t细胞受体和应用 |
| WO2022036495A1 (en) | 2020-08-17 | 2022-02-24 | Utc Therapeutics Inc. | Lymphocytes-antigen presenting cells co-stimulators and uses thereof |
| WO2022111562A1 (zh) * | 2020-11-26 | 2022-06-02 | 上海医药集团生物治疗技术有限公司 | 一种经修饰的免疫细胞及其应用 |
| EP4305627A4 (en) * | 2021-03-12 | 2025-07-02 | Adaptive Biotechnologies Corp | METHODS RELATING TO CROHN'S DISEASE-ASSOCIATED T CELL RECEPTOR |
| US20240150472A1 (en) | 2021-03-17 | 2024-05-09 | Daiichi Sankyo Company, Limited | Gene coding for chimeric receptor for anti-acetylcholine receptor autoantibody |
| CN115505572B (zh) * | 2021-06-22 | 2025-11-14 | 康立泰生物医药(青岛)有限公司 | 一种增强型抗肿瘤nk细胞及其制备方法和应用 |
| EP4511057A1 (en) * | 2022-06-06 | 2025-02-26 | Caribou Biosciences, Inc. | Treatment of autoimmune diseases with engineered immune cells |
| CN116083369B (zh) * | 2022-09-01 | 2025-05-09 | 华中科技大学同济医学院附属同济医院 | 双特异性抗体修饰囊泡、双特异性抗体、核酸、重组载体、基因工程细胞、方法和应用 |
| WO2024077256A1 (en) | 2022-10-07 | 2024-04-11 | The General Hospital Corporation | Methods and compositions for high-throughput discovery ofpeptide-mhc targeting binding proteins |
| WO2024124044A1 (en) | 2022-12-07 | 2024-06-13 | The Brigham And Women’S Hospital, Inc. | Compositions and methods targeting sat1 for enhancing anti¬ tumor immunity during tumor progression |
| WO2025059533A1 (en) | 2023-09-13 | 2025-03-20 | The Broad Institute, Inc. | Crispr enzymes and systems |
| WO2025064482A2 (en) * | 2023-09-19 | 2025-03-27 | Ginkgo Bioworks, Inc. | Chimeric immune cell receptors |
| CN117106035B (zh) * | 2023-10-25 | 2024-04-23 | 烟台药物研究所 | 一种肿瘤靶向多肽、多肽偶联药物及制备与应用 |
| WO2025097055A2 (en) | 2023-11-02 | 2025-05-08 | The Broad Institute, Inc. | Compositions and methods of use of t cells in immunotherapy |
| WO2025117544A1 (en) | 2023-11-29 | 2025-06-05 | The Broad Institute, Inc. | Engineered omega guide molecule and iscb compositions, systems, and methods of use thereof |
Family Cites Families (89)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA120409A (en) | 1909-05-13 | 1909-09-07 | Hiram Lucas Piper | Signal lamp |
| FR901228A (fr) | 1943-01-16 | 1945-07-20 | Deutsche Edelstahlwerke Ag | Système d'aimant à entrefer annulaire |
| US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
| US4716111A (en) | 1982-08-11 | 1987-12-29 | Trustees Of Boston University | Process for producing human antibodies |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4694778A (en) | 1984-05-04 | 1987-09-22 | Anicon, Inc. | Chemical vapor deposition wafer boat |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5413923A (en) | 1989-07-25 | 1995-05-09 | Cell Genesys, Inc. | Homologous recombination for universal donor cells and chimeric mammalian hosts |
| US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| ES2284161T3 (es) | 1990-01-12 | 2007-11-01 | Amgen Fremont Inc. | Generacion de anticuerpos xenogenicos. |
| US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| AU8507191A (en) | 1990-08-29 | 1992-03-30 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| US5199942A (en) | 1991-06-07 | 1993-04-06 | Immunex Corporation | Method for improving autologous transplantation |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| GB9125768D0 (en) | 1991-12-04 | 1992-02-05 | Hale Geoffrey | Therapeutic method |
| US6080840A (en) | 1992-01-17 | 2000-06-27 | Slanetz; Alfred E. | Soluble T cell receptors |
| US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
| US5350674A (en) | 1992-09-04 | 1994-09-27 | Becton, Dickinson And Company | Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| US5993434A (en) | 1993-04-01 | 1999-11-30 | Genetronics, Inc. | Method of treatment using electroporation mediated delivery of drugs and genes |
| AU678843B2 (en) | 1993-08-10 | 1997-06-12 | W.L. Gore & Associates, Inc. | Cell encapsulating device |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| EP0822830B1 (en) | 1995-04-27 | 2008-04-02 | Amgen Fremont Inc. | Human anti-IL-8 antibodies, derived from immunized xenomice |
| WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5626561A (en) | 1995-06-07 | 1997-05-06 | Gore Hybrid Technologies, Inc. | Implantable containment apparatus for a therapeutical device and method for loading and reloading the device therein |
| CA2190628C (en) | 1995-06-07 | 2000-05-30 | Mark D. Butler | An implantable containment apparatus for a therapeutical device and method for loading and reloading the device therein |
| WO1997010807A1 (en) | 1995-09-22 | 1997-03-27 | Gore Hybrid Technologies, Inc. | Improved cell encapsulation device |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| ATE549918T1 (de) | 1996-12-03 | 2012-04-15 | Amgen Fremont Inc | Menschliche antikörper, die ausdrücklich menschliches tnf alpha binden |
| US6261281B1 (en) | 1997-04-03 | 2001-07-17 | Electrofect As | Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells |
| TR199902553T2 (xx) | 1997-04-14 | 2000-03-21 | Micromet Gesellschaft F�R Biomedizinische Forschung Mbh | �nsan v�cuduna kar�� antijen resept�rlerinin �retimi i�in yeni metod ve kullan�mlar�. |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| US6055453A (en) | 1997-08-01 | 2000-04-25 | Genetronics, Inc. | Apparatus for addressing needle array electrodes for electroporation therapy |
| US6241701B1 (en) | 1997-08-01 | 2001-06-05 | Genetronics, Inc. | Apparatus for electroporation mediated delivery of drugs and genes |
| US6678556B1 (en) | 1998-07-13 | 2004-01-13 | Genetronics, Inc. | Electrical field therapy with reduced histopathological change in muscle |
| US7171264B1 (en) | 1999-05-10 | 2007-01-30 | Genetronics, Inc. | Intradermal delivery of active agents by needle-free injection and electroporation |
| CA2401327C (en) | 2000-03-03 | 2014-05-06 | Valentis, Inc. | Nucleic acid formulations comprising poly-amino acids for gene delivery and methods of use |
| AU2001247616B2 (en) | 2000-04-11 | 2007-06-14 | Genentech, Inc. | Multivalent antibodies and uses therefor |
| EP1188825A1 (en) * | 2000-09-18 | 2002-03-20 | Universiteit Leiden | T cell receptor transfer into a candidate effector cell or a precursor thereof |
| DE10109854A1 (de) | 2001-03-01 | 2002-09-12 | Thomas Stanislawski | Polypeptide eines hdm2-Protein spezifischen murinen alpha/beta T-Zell Rezeptors, diese kodierende Nukleinsäuren und deren Verwendung |
| US8209006B2 (en) | 2002-03-07 | 2012-06-26 | Vgx Pharmaceuticals, Inc. | Constant current electroporation device and methods of use |
| US20070274998A1 (en) | 2002-04-29 | 2007-11-29 | Genpatzz Pharmacogentetics Ag | Novel Bispecific Molecules For Use In Therapy And Diagnosis |
| US20040014645A1 (en) | 2002-05-28 | 2004-01-22 | Advisys, Inc. | Increased delivery of a nucleic acid construct in vivo by the poly-L-glutamate ("PLG") system |
| US7446190B2 (en) | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
| US7328064B2 (en) | 2002-07-04 | 2008-02-05 | Inovio As | Electroporation device and injection apparatus |
| US20050070841A1 (en) | 2002-07-04 | 2005-03-31 | Inovio As | Electroporation device and injection apparatus |
| DE10244457A1 (de) * | 2002-09-24 | 2004-04-01 | Johannes-Gutenberg-Universität Mainz | Verfahren zur rationalen Mutagenese von alpha/beta T-Zell Rezeptoren und entsprechend mutierte MDM2-Protein spezifische alpha/beta T-Zell Rezeptoren |
| EP1641818B1 (en) | 2003-07-04 | 2008-12-03 | Affibody AB | Polypeptides having binding affinity for her2 |
| EP1732613A2 (en) | 2004-04-06 | 2006-12-20 | Affibody AB | Use of serum albumin binding peptides conjugates for the preparation of a medicament |
| EP1611850A1 (fr) * | 2004-06-28 | 2006-01-04 | Cardio Life Research S.A. | Dispositif d'occlusion et de ponction étanche pour structure anatomique. |
| EP1769078A1 (en) * | 2004-07-01 | 2007-04-04 | VIRxSYS Corporation | Vector packaging cell line |
| US7585960B2 (en) | 2005-05-11 | 2009-09-08 | Theramab Gmbh | Nucleic acids encoding superagonistic anti-CD28 antibodies |
| CA2612241C (en) | 2005-07-01 | 2018-11-06 | Medarex, Inc. | Human monoclonal antibodies to programmed death ligand 1 (pd-l1) |
| GB0524788D0 (en) | 2005-12-05 | 2006-01-11 | Affibody Ab | Polypeptides |
| EP1957642A2 (en) | 2005-12-07 | 2008-08-20 | Genetronics, Inc. | Variable volume electroporation chamber and methods therefore |
| US8426557B2 (en) | 2007-08-03 | 2013-04-23 | Affibody Ab | IGF-1R binding polypeptides and their use |
| EP2072525A1 (en) | 2007-12-21 | 2009-06-24 | Affibody AB | New polypeptides having affinity for HER2 |
| EP3663318A1 (en) | 2008-01-07 | 2020-06-10 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
| AU2009308707A1 (en) | 2008-10-31 | 2010-05-06 | Biogen Idec Ma Inc. | LIGHT targeting molecules and uses thereof |
| JO3096B1 (ar) | 2008-11-07 | 2017-03-15 | Imclone Llc | الأجسام المضادة لمستقبل ii مضاد tgfb |
| GB0911566D0 (en) * | 2009-07-03 | 2009-08-12 | Immunocore Ltd | T cell receptors |
| GB0917090D0 (en) * | 2009-09-29 | 2009-11-11 | Ucl Biomedica Plc | T-cell receptor |
| CN102597222B (zh) * | 2009-10-27 | 2015-07-15 | 因缪尼卡姆股份公司 | 用于增殖抗原特异性t细胞的方法 |
| EP2501722A4 (en) * | 2009-11-19 | 2013-05-01 | Univ Singapore | METHOD FOR PRODUCING T-CELL-RECEPTOR-SIMILAR MONOCLONAL ANTIBODIES AND APPLICATIONS THEREOF |
| CN103124740B (zh) * | 2010-09-21 | 2015-09-02 | 美国卫生和人力服务部 | 抗-ssx-2t细胞受体和相关材料及使用方法 |
| NZ723974A (en) * | 2010-10-27 | 2017-03-31 | Baylor College Medicine | Chimeric cd27 receptors for redirecting t cells to cd70-positive malignancies |
| PH12014500247A1 (en) | 2011-07-29 | 2014-03-24 | Univ Pennsylvania | Switch costimulatory receptors |
| JP5737082B2 (ja) | 2011-08-31 | 2015-06-17 | 富士通株式会社 | ポインタ位置補正方法、ポインタ位置補正プログラムおよびサーバ装置 |
| US10421960B2 (en) | 2011-09-16 | 2019-09-24 | The Trustees Of The University Of Pennsylvania | RNA engineered T cells for the treatment of cancer |
| EP3594245A1 (en) * | 2012-02-13 | 2020-01-15 | Seattle Children's Hospital d/b/a Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
| AU2013289971A1 (en) * | 2012-07-13 | 2015-01-22 | The Trustees Of The University Of Pennsylvania | Enhancing activity of CAR T cells by co-introducing a bispecific antibody |
| SG11201502598SA (en) | 2012-10-02 | 2015-05-28 | Sloan Kettering Inst Cancer | Compositions and methods for immunotherapy |
| BR112015020516A2 (pt) | 2013-02-26 | 2017-10-10 | Memorial Sloan Kettering Cancer Center | composições e métodos para imunoterapia |
| JP6420776B2 (ja) * | 2013-03-05 | 2018-11-07 | ベイラー カレッジ オブ メディスンＢａｙｌｏｒ Ｃｏｌｌｅｇｅ Ｏｆ Ｍｅｄｉｃｉｎｅ | 免疫療法のためのエンゲージャー細胞 |
| TWI654206B (zh) * | 2013-03-16 | 2019-03-21 | 諾華公司 | 使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症 |
| MA41538A (fr) * | 2014-10-17 | 2017-12-26 | Baylor College Medicine | Cellules immunitaires bipartites et tripartites de signalisation |
-
2015
- 2015-10-30 AU AU2015338984A patent/AU2015338984A1/en not_active Abandoned
- 2015-10-30 US US15/518,922 patent/US20170258835A1/en active Pending
- 2015-10-30 PT PT158550137T patent/PT3212225T/pt unknown
- 2015-10-30 PL PL15855013.7T patent/PL3212225T3/pl unknown
- 2015-10-30 WO PCT/US2015/058339 patent/WO2016070061A1/en not_active Ceased
- 2015-10-30 SI SI201532095T patent/SI3212225T1/sl unknown
- 2015-10-30 EP EP15855013.7A patent/EP3212225B1/en active Active
- 2015-10-30 KR KR1020177014658A patent/KR20170074243A/ko not_active Withdrawn
- 2015-10-30 HK HK18102826.6A patent/HK1243333A1/zh unknown
- 2015-10-30 CN CN201580071613.7A patent/CN107106670A/zh active Pending
- 2015-10-30 EP EP25207728.4A patent/EP4653013A3/en active Pending
- 2015-10-30 JP JP2017523266A patent/JP7372728B2/ja active Active
- 2015-10-30 CA CA2964958A patent/CA2964958A1/en not_active Abandoned
- 2015-10-30 ES ES15855013T patent/ES3061201T3/es active Active
-
2021
- 2021-05-19 JP JP2021084334A patent/JP2021121208A/ja not_active Withdrawn
-
2023
- 2023-05-30 JP JP2023088510A patent/JP7757343B2/ja active Active
-
2025
- 2025-10-08 JP JP2025169833A patent/JP2025188145A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Rezvani et al. | Engineering natural killer cells for cancer immunotherapy | |
| Zhang et al. | Chimeric antigen receptor-based natural killer cell immunotherapy in cancer: from bench to bedside | |
| JP2017535261A5 (enExample) | ||
| Daher et al. | CAR‐NK cells: the next wave of cellular therapy for cancer | |
| JP2021058196A5 (enExample) | ||
| Shimasaki et al. | Expanded and armed natural killer cells for cancer treatment | |
| JP2017533707A5 (enExample) | ||
| Du et al. | Therapeutic potential of natural killer cells in gastric cancer | |
| JP7270253B2 (ja) | ナチュラルキラー細胞のエクスビボ拡大及び活性化のための刺激細胞株 | |
| Wang et al. | Chimeric antigen receptor (CAR)-modified NK cells against cancer: Opportunities and challenges | |
| JP6022667B2 (ja) | 炎症性ヒトＴｈ１７細胞の増殖および機能を決定的に調節するＩＣＯＳ | |
| CN102597223B (zh) | 生产天然杀伤细胞的方法 | |
| IL259120A (en) | Her2-targeted antigen chimeric receptors2 | |
| JP2018504910A5 (enExample) | ||
| ES2910227T3 (es) | Composición y métodos para la estimulación y expansión de células T | |
| JP2018533625A5 (enExample) | ||
| CN105848484A (zh) | 用于免疫治疗的多克隆γδ T细胞 | |
| JP2019500894A5 (enExample) | ||
| IL292650A (en) | Chimeric antigen receptor T cells target il13ra2 | |
| BR112020018670A2 (pt) | Receptor de antígeno quimérico de receptor alfa 2 da il-13 (il13ra2) para imunoterapia com células t específicas para tumor | |
| US20160237407A1 (en) | Universal donor chimeric antigen receptor cells | |
| JP7680032B2 (ja) | Ａ２／ｎｙ－ｅｓｏ－１特異的ｔ細胞受容体およびその使用 | |
| Kintz et al. | Inclusion of Dap10 or 4-1BB costimulation domains in the chPD1 receptor enhances anti-tumor efficacy of T cells in murine models of lymphoma and melanoma | |
| US11473059B2 (en) | Method for enrichment and expansion of virus antigen-specific T cells | |
| JP2022512538A5 (enExample) |